viewSareum Holdings PLC

Sareum Holdings PLC heartened by Sierra Oncology progress

Sareum Holdings Plc (LON:SAR) chief executive, Dr Tim Mitchell, talked to Proactive Investors’ Andrew Scott about Sierra Oncology, which is the licence-holder for the Sareum-developed SRA737 cancer drug.

Mitchell said he's heartened Sierra is more than doubling the size of two phase II clinical trials of the treatment (one underway, the other upcoming).

He is also impressed by the methodology used by Sierra’s researchers that is hoped will glean the best results.

“Rather than screen all-comers they [Sierra] are looking to pre-screen patients for mutations that are most likely to respond to CHK-1 [checkpoint kinase 1] inhibitors so the chances of seeing efficacy we hope are very good,” he told Proactive’s Scott.

Quick facts: Sareum Holdings PLC

Price: 1.55 GBX

Market: AIM
Market Cap: £50.65 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...


Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read